ClinicalTrials.gg

Program

lorigerlimab

Also written as “Lorigerlimab”.

Its studies are mostly in Prostatic Neoplasms, Castration-Resistant · Endometrial Neoplasms · Melanoma, led by MacroGenics.

Furthest: phase 2, since Apr 17, 20234 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MacroGenics41 open or runningphase 2since Apr 17, 2023Nov 29, 2018Jul 2027phase 2 · NCT06730347

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2018First study: phase 1 study in MelanomaFirst studyNCT03761017 · 162 enrolled · United States, Bulgaria, Poland and more
  2. Feb 12, 2022Phase 1 study in Prostatic Neoplasms, Castration-ResistantNCT05293496 · 31 enrolled · United States
  3. Apr 17, 2023Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT05848011 · 154 enrolled · United States, Australia, Belgium and more
  4. Dec 9, 2024Phase 2 study in Endometrial NeoplasmsNCT06730347 · 80 planned · United States, Canada, South Korea

Ahead

  1. Jul 2027Primary completion: phase 2 study in Endometrial NeoplasmsNCT06730347

TargetBeta

CTLA4 →PDCD1 →read by rule
“A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06730347Endometrial Neoplasms · United States, Canada, South Korea2RecruitingJul 202780
NCT05848011Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more2CompletedFeb 19, 2026154
NCT05293496Prostatic Neoplasms, Castration-Resistant · United States1CompletedJun 24, 202531
NCT03761017Melanoma · United States, Bulgaria, Poland and more1CompletedAug 29, 2024162

How it is read

Names in the registry

  • “Lorigerlimab”, 2 entries
  • “lorigerlimab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.